Telomere Science Library

Publications, Presentations, and Videos
about the Nobel-Prize Winning Science of Telomere Biology

Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.

Authors: Dong-Sheng DS. Huang, Zhaohui Z. Wang, Xu-Jun XJ. He, Bill H BH. Diplas, Rui R. Yang, Patrick J PJ. Killela, Qun Q. Meng, Zai-Yuan ZY. Ye, Wei W. Wang, Xiao-Ting XT. Jiang, Li L. Xu, Xiang-Lei XL. He, Zhong-Sheng ZS. Zhao, Wen-Juan WJ. Xu, Hui-Ju HJ. Wang, Ying-Yu YY. Ma, Ying-Jie YJ. Xia, Li L. Li, Ru-Xuan RX. Zhang, Tao T. Jin, Zhong-Kuo ZK. Zhao, Ji J. Xu, Sheng S. Yu, Fang F. Wu, Junbo J. Liang, Sizhen S. Wang, Yuchen Y. Jiao, Hai H. Yan, Hou-Quan HQ. Tao
Published: 04/02/2015, European journal of cancer (Oxford, England : 1990)


Several somatic mutation hotspots were recently identified in the telomerase reverse transcriptase (TERT) promoter region in human cancers. Large scale studies of these mutations in multiple tumour types are limited, in particular in Asian populations. This study aimed to: analyse TERT promoter mutations in multiple tumour types in a large Chinese patient cohort, investigate novel tumour types and assess the functional significance of the mutations.


TERT promoter mutation status was assessed by Sanger sequencing for 13 different tumour types and 799 tumour tissues from Chinese cancer patients. Thymic epithelial tumours, gastrointestinal leiomyoma, and gastric schwannoma were included, for which the TERT promoter has not been previously sequenced. Functional studies included TERT expression by reverse-transcriptase quantitative polymerase chain reaction (RT-qPCR), telomerase activity by the telomeric repeat amplification protocol (TRAP) assay and promoter activity by the luciferase reporter assay.


TERT promoter mutations were highly frequent in glioblastoma (83.9%), urothelial carcinoma (64.5%), oligodendroglioma (70.0%), medulloblastoma (33.3%) and hepatocellular carcinoma (31.4%). C228T and C250T were the most common mutations. In urothelial carcinoma, several novel rare mutations were identified. TERT promoter mutations were absent in gastrointestinal stromal tumour (GIST), thymic epithelial tumours, gastrointestinal leiomyoma, gastric schwannoma, cholangiocarcinoma, gastric and pancreatic cancer. TERT promoter mutations highly correlated with upregulated TERT mRNA expression and telomerase activity in adult gliomas. These mutations differentially enhanced the transcriptional activity of the TERT core promoter.


TERT promoter mutations are frequent in multiple tumour types and have similar distributions in Chinese cancer patients. The functional significance of these mutations reflect the importance to telomere maintenance and hence tumourigenesis, making them potential therapeutic targets.

Copyright © 2015 Elsevier Ltd. All rights reserved.
PubMed Full Text